SCHEMBL1190922

SCHEMBL1190922

C1CN[C@H](CN2CCOCC2)C1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.44
HTR1D P28221 1/20 0.44
HTR2A P28223 1/20 0.44
HRH1 P35367 1/20 0.44
ADRA1B P35368 1/20 0.44
KCNH2 Q12809 1/20 0.44
DPP4 P27487 1/20 0.41
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
GAA P10253 2/20 0.39
CACNA2D1 P54289 1/20 0.38
CACNA1B Q00975 1/20 0.38
CACNB1 Q02641 1/20 0.38
ARG1 P05089 3/20 0.33
ARG2 P78540 1/20 0.33
PARP14 Q460N5 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7032911 1.00 HTR1A (0.44) HTR1AHTR1DHTR2AHRH1ADRA1B
SCHEMBL1190924 1.00 HTR1A (0.44) HTR1AHTR1DHTR2AHRH1ADRA1B
Hydrochloric Acid SCHEMBL27899317 0.98 HTR1A (0.43) HTR1AHTR1DHTR2AHRH1ADRA1B
Hydrochloric Acid SCHEMBL1190265 0.98 HTR1A (0.43) HTR1AHTR1DHTR2AHRH1ADRA1B
SCHEMBL10326397 0.94 HTR1A (0.50) HTR1AHTR1DHTR2AHRH1ADRA1B
SCHEMBL8562869 0.94 HTR1A (0.50) HTR1AHTR1DHTR2AHRH1ADRA1B
SCHEMBL10326175 0.94 HTR1A (0.50) HTR1AHTR1DHTR2AHRH1ADRA1B
Hydrochloric Acid SCHEMBL11144978 0.93 HTR1A (0.49) HTR1AHTR1DHTR2AHRH1ADRA1B
SCHEMBL488775 0.84 HTR1A (0.45) HTR1AHTR1DHTR2AHRH1ADRA1B
SCHEMBL22507863 0.84 HTR1A (0.45) HTR1AHTR1DHTR2AHRH1ADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021070658-A1 METHOD FOR PRODUCING CYCLOPENTANE COMPOUND, METHOD FOR PRODUCING LACTONE COMPOUND, METHOD FOR PRODUCING DIOL COMPOUND, AND COMPOUND 国立大学法人東北大学 2021-04-15 WO disclosed
WO-2017017630-A1 NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2017-02-02 WO disclosed
EP-2438989-B1 USE OF ASYMMETRIC HYDROGENATION CATALYST TAKASAGO PERFUMERY CO LTD (JP) 2016-04-13 EP disclosed
EP-2217226-B1 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2015-07-22 EP disclosed
US-8716500-B2 Method for producing five-membered ring-containing compound ONO PHARMACEUTICAL CO., LTD. (JP) 2014-05-06 US disclosed
US-8716500-B2 Method for producing five-membered ring-containing compound ONO PHARMACEUTICAL CO., LTD. (JP) 2014-05-06 US disclosed
US-20140051874-A1 METHOD FOR PRODUCING FIVE-MEMBERED RING-CONTAINING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2014-02-20 US disclosed
US-20140051874-A1 METHOD FOR PRODUCING FIVE-MEMBERED RING-CONTAINING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2014-02-20 US disclosed
US-20130045962-A1 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC 2013-02-21 US disclosed
CN-101917981-B Peptide deformylase inhibitors SMITHKLINE BEECHAM CORP 2012-11-14 CN disclosed
EP-1287001-B1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PROD INC (US) 2004-09-29 EP disclosed
US-20040186134-A1 Sulfonamide lactam inhibitors of FXa and method O'CONNOR STEPHEN P (US) 2004-09-23 US disclosed
US-6555542-B1 Factor Xa (FXa); useful as anticoagulants in the treatment of cardiovascular diseases associated with thrombosis BRISTOL-MYERS SQUIBB COMPANY 2003-04-29 US disclosed
EP-1287001-A1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2003-03-05 EP disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 WO disclosed
US-20020042409-A1 Thiophene derivatives useful as anticancer agents PFIZER PRODUCTS INC. 2002-04-11 US disclosed
WO-2001094353-A1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2001-12-13 WO disclosed
EP-0156191-B1 CONDENSED DIAZEPINONES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS Dr. Karl Thomae GmbH (DE) 1989-07-19 EP disclosed
US-4550107-A Condensed diazepinones, their compositions and methods of use as pharmaceuticals DR. KARL THOMAE GMBH (DE) 1985-10-29 US disclosed
EP-0156191-A2 Condensed diazepinones, process for their preparation and medicaments containing these compounds Dr. Karl Thomae GmbH (DE) 1985-10-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051874-A1 METHOD FOR PRODUCING FIVE-MEMBERED RING-CONTAINING COMPOUND PTGIS, ALOX5, PTGES HTR1A 2945/4885HTR1D 1859/4885HTR2A 3642/4885
US-20130045962-A1 PEPTIDE DEFORMYLASE INHIBITORS PDF, DPEP1, DHPS HTR1A 3258/4885HTR1D 2874/4885HTR2A 2761/4885
US-20040186134-A1 Sulfonamide lactam inhibitors of FXa and method STS, SULT1E1, F8 HTR1A 1453/4885HTR1D 2085/4885HTR2A 2765/4885
US-20020042409-A1 Thiophene derivatives useful as anticancer agents TP53, RCC1, CCNA1 HTR1A 2257/4885HTR1D 1059/4885HTR2A 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.